News | April 28, 2024
Apollo HealthCo to raise Rs. 2,475 crore from Advent International
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
New solvent-free micronization technology expanded at the Darmstadt site in Germany
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Subscribe To Our Newsletter & Stay Updated
